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Hemopexin and α1-microglobulin act as scavengers to eliminate free heme-groups respon-
sible for hemoglobin-induced oxidative stress. The present study evaluated maternal and
fetal plasma concentrations of these scavengers in the different phenotypes of placenta-
mediated disorders. Singleton pregnancies with normotensive fetal growth restriction [FGR]
(n = 47), preeclampsia without FGR (n = 45) and preeclampsia with FGR (n = 51) were
included prospectively as well as uncomplicated pregnancies (n = 49). Samples were col-
lected at delivery and ELISA analysis was applied to measure the hemopexin and α1-micro-
globulin concentrations. In maternal blood in preeclampsia with and without FGR,
hemopexin was significantly lower (p = 0.003 and p<0.001, respectively) and α1-microglobu-
lin was significantly higher (p<0.001 in both) whereas no difference existed in normotensive
FGR mothers compared to controls. In contrast, in fetal blood in growth restricted fetuses
with and without preeclampsia, both hemopexin and α1-microglobulin were significantly
lower (p<0.001 and p = 0.001 for hemopexin, p = 0.016 and p = 0.013 for α1-microglobulin,
respectively) with no difference in fetuses from preeclampsia without FGR in comparison to
controls. Thus, hemopexin and α1-microglobulin present significantly altered concentrations
in maternal blood in the maternal disease -preeclampsia- and in cord blood in the fetal dis-
ease -FGR-, which supports their differential role in placenta-mediated disorders in accor-
dance with the clinical presentation of these disorders.
Introduction
Preeclampsia (PE) and fetal growth restriction (FGR) constitute a great challenge in modern
obstetrics since they affect 2–5% and 5–10% of pregnancies, respectively [1, 2]. PE is responsi-
ble for significant maternal and perinatal morbidity and mortality worldwide [3]. In addition,
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FGR has a great burden on fetal well-being and half of the stillbirths are associated with FGR
[4]. The exact pathogenesis of PE and FGR is still poorly understood which prevents the devel-
opment of specific treatments that may prolong the pregnancy and minimize the complica-
tions of these disorders. Both of PE and FGR are considered being placenta-mediated
disorders since they are characterized by insufficient perfusion of the placenta associated with
oxidative stress and local hypoxia [5–7]. Recently, cell-free hemoglobin including free fetal
hemoglobin (HbF) has been reported to be related to PE and concomitant FGR [8, 9]. An up-
regulation of HbF gene expression has been observed in placentas from PE pregnancies
together with placental HbF accumulation most likely secondary to hypoxia [10]. Additionally,
the experimental evidence of human placental hemoglobin perfusion resulted in physiological
and morphological changes similar to PE placentas [10, 11]. Cell-free hemoglobin has pro-oxi-
dant and inflammatory properties [12] and is associated with endothelial dysfunction and car-
diovascular complications in hemolytic disorders [13]. Increased cell-free hemoglobin levels
have also been reported in maternal plasma from pregnancies complicated by PE [7, 14] and
cord blood from fetuses affected by FGR associated with PE, overall hemoglobin-induced oxi-
dative stress was proposed to contribute to the development of these conditions [9, 15].
To prevent the toxic effect of free hemoglobin and its degradation compounds heme and
free iron, the human body disposes of several circulating scavenger proteins. Haptoglobin is
the main well studied hemoglobin scavenger, that collects most of the cell-free hemoglobin
and carries it to macrophages and hepatocytes [16]. Another important heme scavenger is
hemopexin, which is an acute phase glycoprotein synthesized by the liver that has a high affin-
ity to bind free heme [17]. When the haptoglobin system gets saturated, hemopexin frees the
blood from heme [18]. In addition, α1-microglobulin (A1M) is an alternative heme scavenging
protein that binds heme and radicals and has enzymatic neutralizing capability. Recently,
A1M has been shown to be up-regulated in early [19, 20] and late-onset PE [14, 21]. However,
there is still a knowledge gap regarding the involvement of the heme scavengers in PE with
and without FGR as well as in normotensive FGR.
Thus, the objective of this study was to evaluate paired maternal and fetal plasma samples
for concentrations of hemopexin and A1M in the different phenotypes of PE and/or FGR
compared to uncomplicated pregnancies.
Methods
Study population
This was a prospective observational study including singleton pregnancies with a diagnosis of
PE and/or FGR that attended the Departments of Maternal-Fetal Medicine at BCNatal (Barce-
lona, Spain) between January 2016 and December 2017. Fetal growth restriction was defined
as estimated fetal weight (EFW) and birthweight below the 10th centile associated with either
abnormal cerebroplacental ratio (<5th centile) or abnormal uterine arteries mean pulsatility
index (>95th centile), or birthweight below the 3rd centile [22]. The EFW and birthweight cen-
tiles were assigned according to local standards [23]. Preeclampsia was defined as high blood
pressure (systolic blood pressure�140 mmHg and/or diastolic blood pressure�90 mmHg on
two occasions, at least four hours apart) that developed after 20 weeks of gestation, and was
combined with proteinuria (�300 mg/24 hours or protein/creatinine ratio�0.3) [1, 24].
Uncomplicated pregnancies with normotensive mothers and appropriate growth for gesta-
tional age fetuses -defined as EFW and birthweight above the 10th centile- were randomly
selected from our general population to be included as controls and frequency paired with
cases. Spontaneous preterm deliveries without clinical signs of infection, or iatrogenic preterm
deliveries due to placenta previa were recruited as preterm controls. Preterm deliveries were
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considered when gestational age at delivery was�24 and<37 weeks gestation. Term deliveries
included pregnancies with gestational age at delivery�37 and<42 weeks of gestation. In all
pregnancies, gestational age was calculated based on the crown-rump length at first trimester
ultrasound [25]. Pregnancies with chromosomal/structural anomalies or intrauterine infection
were excluded. The study was conducted in accordance with the principles of the Helsinki dec-
laration and the relevant guidelines and regulations. The study protocol was approved by the
ethical committee of clinical research at Hospital Clı́nic, Barcelona, Spain (HCB/2016/0253)
and patients accepting to participate provided their written informed consent.
Data collection and study protocol
The following data were recorded upon enrollment: maternal age, ethnicity, body mass index
(BMI), known chronic disease (i.e., hypertension, diabetes mellitus), parity, obstetric history,
mode of conception and smoking status. The feto-placental Doppler parameters were obtained
in the last 2 weeks of pregnancy. Ultrasound studies were performed using a Siemens Sonoline
Antares (Siemens Medical Systems, Malvern, PA, USA) or a Voluson 730 Expert (GE Medical
Systems, Milwaukee, WI, USA) with 6–4-MHz linear curved-array probes. The EFW was cal-
culated using the Hadlock formula [26] and centile was based on local reference curves [23].
All estimations were done in the absence of fetal movements and, when required, with the
mother in voluntary suspended respiration. An angle of insonation of<30˚ between the vessel
and the Doppler beam was accepted for analysis. The mechanical and thermal indices were
maintained below 1, and the wall filter was set to 70 Hz. Feto-placental Doppler parameters
were obtained from three or more successive waveforms in each vessel. Doppler examination
included uterine arteries (UtA) [27], umbilical artery (UA) [28] and the fetal middle cerebral
artery (MCA) pulsatility indices (PI) [28], with the calculation of the cerebroplacental ratio
(CPR) [29]. These values were normalized into z-scores accordingly [27–29].
At time of delivery, maternal serum creatinine, admissions to the intensive care unit, gesta-
tional age, birthweight, birthweight centile, Apgar scores, umbilical artery pH, admissions to
the neonatal intensive care unit and perinatal mortality were recorded. In addition, paired
maternal and cord blood were collected to measure the concentrations of Hemopexin and
A1M. Pregnancies with missing perinatal outcomes or unconfirmed FGR diagnosis (a small
newborn not fulfilling FGR definition with birthweight between the 3rd and the 10th centile
associated with normal cerebroplacental ratio (�5th centile) and normal uterine arteries PI
(�95th centile)) [22] were excluded as shown in Fig 1.
Follow up and management
All pregnancies with FGR diagnosis were monitored fortnightly with fetal growth evaluation,
amniotic fluid assessment and Doppler measurements. The management of these pregnancies
relied on a standardized protocol [22]. Indications for labor induction were as follows: 1) at
�26 weeks’ gestation: non-reassuring cardiotocography register and/or reversed ductus
venosus (DV) diastolic flow 2) at�30 weeks’ gestation, one or more of the following: UA
reversed end diastolic volume, DV-PI�95th centile, DV absent diastolic flow 3) at�34 weeks’
gestation: UA absent end diastolic volume 4) at�37 weeks’ gestation, one or more of the fol-
lowing: estimated fetal weight <3rd centile, persistent (12 h apart) MCA-PI <5th centile or
UA-PI > 95th centile or CPR <5th centile, UtA-PI >95th centile 5) at�40 weeks’ gestation,
estimated fetal weight�3rd and<10th centile with normal Doppler parameters. In the first
three scenarios, termination of pregnancy was by cesarean section, whereas in the next two by
labor induction.
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Pregnancies diagnosed with PE were classified as mild (to be terminated at�37 weeks) and
severe (to be terminated at�34 weeks or before if applies). Severe PE was considered accord-
ing to the criteria of the American College of Obstetricians and Gynecologists [24]. Pregnancy
termination was by labor induction or cesarean section upon obstetric indication.
Labor induction was achieved by hormonal cervical ripening with a slow-release prosta-
glandin E2 vaginal pessary (10mg) or mechanical with foley catheter. Oxytocin induction was
indicated thereafter for failure of labor onset within 18h. During the labor course, cesarean or
operative vaginal delivery was indicated for non-reassuring fetal status, based on abnormal
fetal heart rate tracing [30] and adverse fetal scalp blood pH during intrapartum monitoring.
Paired maternal and cord blood sampling
Maternal blood samples were drawn from peripheral veins around delivery (up to a maximum
of 2 hours after delivery). Cord blood was obtained from the umbilical arteries after the cord
was clamped at delivery. All blood samples were collected in EDTA-treated tubes. Plasma was
separated by centrifugation at 1500 g for 10 min at 4˚C, and samples were immediately stored
at −80˚C until analyzed.
Heme scavengers and other biomarkers
Hemopexin concentrations. Hemopexin concentrations were determined using a
Human Hemopexin ELISA Kit GWB-4B6D1A from Genway Biotech Inc (San Diego, CA,
USA) according to manufacturer’s instructions. Standards and unknown samples were run in
duplicates and the absorbance was read at 450nm using a Wallac 1420 Multilabel Counter
(Perkin Elmer Life Sciences, Waltham, MA, USA).
A1M concentrations. An in-house developed sandwich ELISA was used for the quantifi-
cation of A1M. Microtiter plates were coated with an anti-human A1M antibody (mouse
monoclonal, clone 35.14; 5 μg/ml in PBS) overnight at +4˚C under sealing film with 100 ml/
well. After washing three times with PBS C 0.05% tween-20, 100 ml of human urinary A1M
Fig 1. The flow chart of the study. FGR, fetal growth restriction; PE, preeclampsia.
https://doi.org/10.1371/journal.pone.0239030.g001
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reference standard samples (1.56–100 ng/ml in PBS C 0.05% tween-20) or unknown plasma
samples (diluted 1000x with PBS C 0.05% tween-20) were added to the wells and incubated
under sealing film for 1 h at room temperature, darkness and rotational shaking 250–500 rpm.
After washing three times with PBS C 0.05% tween-20, 100 ml/well of a horseradish peroxidase
(HRP)-conjugated detection antibody (mouse monoclonal, clone 57.10; 5 ng/ml) was added
and incubated under sealing film for 1 hour at room temperature, darkness and rotational
shaking 250–500 rpm. Finally, after washing three times with PBS C 0.05% tween-20, 100 ml/
well of a ready-to-use 3,3´,5,5´-Tetramethylbenzidine (TMB, Life Technologies, Stockholm,
Sweden) substrate solution was added, sealed, and incubated without shaking. The reaction
was stopped after 20 minutes using 1 M sulfuric acid and the absorbance was read at 450nm
using a Wallac 1420 Multilabel Counter (Perkin Elmer Life Sciences, Waltham, MA, USA).
The samples were analyzed in 10 batches (5 for each of maternal and fetal plasma samples). A
standard curve was used to quantify the A1M concentration in each sample with the prepara-
tion of a new standard curve for each plate (an example is presented as S1 Fig in S1 File). The
average intraassay coefficient of variation was 2.23% (±1.8% standard deviation) and 1.21%
(±0.95% standard deviation) for maternal and fetal A1M respectively in harmony with previ-
ous studies [20, 31]. Both anti-human A1M and HRP-conjugated detection antibodies pro-
duced in-house by Agrisera AB (Vännäs, Sweden) by immunization with human urinary A1M
prepared as previously described [32].
Additional biochemical measurements in cord blood samples
To investigate the presence of cell-free hemoglobin in cord blood samples, uncomplexed free
HbF levels were quantified by an in-house developed sandwich ELISA. Microtiter plates were
coated with anti-human HbF antibody (mouse monoclonal, clone 13-47-1; 20μg/ml) overnight
at +4˚C. Standards and unknown samples were added in duplicates and incubated for 2 hours
at room temperature. A biotinylated detection antibody (monoclonal antibody, clone102.11;
4μg/ml) was added and incubated for 1 hour at room temperature. Streptavidin-HRP working
solution cat no S5512; 0.5mg from Sigma-Aldrich was added and incubated for 30 minutes at
room temperature. Finally, a ready-to-use TMB (Life Technologies, Stockholm, Sweden) sub-
strate solution was added. The reaction was stopped after 20 minutes using 1 M sulfuric acid
solution and the absorbance was read at 450nm using a Wallac 1420 Multilabel Counter (Per-
kin Elmer Life Sciences, Waltham, MA, USA). A standard curve was used to quantify the HbF
concentration in each sample. Both anti-human HbF antibody and the biotinylated detection
antibody were prepared in house by immunization with purified human hemoglobin gamma-
chains [14]. Lactate dehydrogenase (LDH) activity was measured to validate the level of
mechanical hemolysis due to sampling using an LDH Assay kit ab102526 from Abcam (Cam-
bridge, United Kingdom). Erythropoietin was measured to evaluate any expressional changes
linked to changes in plasma free HbF levels that might have occurred in vivo. A fully auto-
mated chemiluminescent immunoassay for erythropoietin on an Immulite 2000 analyzer (Sie-
mens Healthineers) was used following the manufacturer’s instructions.
Statistical analysis
Data were analyzed with the statistical software STATA 14.2 (StataCorp LLC, Texas, USA). A
sample size of 35 patients per group was calculated by expecting differences of 3 standard devi-
ations in hemopexin concentrations between each group of the cases and the controls (both in
maternal and cord blood) [9, 21], for a given 5% α error and 80% power.
Results were expressed as mean (± standard deviation), median (interquartile range) or per-
centage, as appropriate. Statistical analysis included the use of student t or Mann Whitney U
PLOS ONE Heme scavengers in preeclampsia and fetal growth restriction
PLOS ONE | https://doi.org/10.1371/journal.pone.0239030 September 11, 2020 5 / 13
tests for continuous variables and Pearson χ2 test for the categorical ones. Each group of the
cases was compared separately with controls. To evaluate the influence of confounding factors,
comparisons were adjusted for the differences in ethnicity, chronic hypertension, diabetes,
smoking, fetal sex and gestational age at time of sampling by multiple regression analyses. In
addition, a sub analysis was performed by dividing the population according to gestational age
at delivery to preterm or term and also to pregnancies with a male or female fetus. To explore
the correlation between maternal hemopexin or A1M and maternal serum creatinine on one
hand, and fetal hemopexin or A1M on the other hand, Pearson correlation coefficient was cal-
culated. Maternal and fetal hemopexin and A1M correlation with pregnancy outcome has
been also explored including time to delivery, case severity, admissions to the intensive care
unit, APGAR score at 5 minutes and neonatal intensive care unit admissions. All reported p
values are two-sided. Differences were considered significant when p<0.05.
Results
Table 1 displays the characteristics of the study population which consisted of 192 patients.
The study groups were comparable regarding maternal age, parity and mode of conception.
Chronic hypertension and pregestational BMI were significantly higher among PE cases,
whereas a higher prevalence of smokers was observed in normotensive FGR with lower preges-
tational BMI, in comparison to controls. As expected, higher uterine and umbilical arteries PI
were present in FGR groups with lower fetal MCA-PI and CPR. In addition, gestational age at
time of delivery was earlier in PE and/or FGR.
The heme scavenger results are shown in Fig 2 and in S1 Table in S1 File. In maternal
blood, hemopexin was significantly lower in PE with and without FGR (p = 0.03, p<0.001)
respectively when compared to controls. In addition, significantly higher concentrations of
A1M (p<0.001) were seen in both groups of PE than controls. Similar concentrations of
hemopexin or A1M concentrations were seen in normotensive FGR and controls (p = 0.48 for
hemopexin, p = 0.54 for A1M). In fetal blood, hemopexin and A1M were significantly lower in
FGR fetuses with and without PE compared to controls (p<0.001, p = 0.001 for hemopexin;
p = 0.016, p = 0.013 for A1M) respectively, and with no difference seen for PE without FGR
(p = 0.06 for hemopexin, p = 0.85 for A1M). These results remained significant after statistical
adjustment for potential confounders such as ethnicity, chronic hypertension, pregestational
diabetes, smoking, fetal sex and gestational age at sampling. In PE mothers, A1M was posi-
tively correlated with creatinine concentrations (r = 0.33, p = 0.002) in contrast to no correla-
tion between hemopexin and creatinine levels (r = -0.01, p = 0.92) as displayed in S2 Fig in S1
File. The FGR fetuses had higher levels of free HbF, LDH activity and erythropoietin in their
blood, compared to controls (S3 Fig in S1 File).
The subanalysis accounting for the differences in the gestational age at delivery showed
comparable concentrations of maternal and fetal hemopexin and A1M in association with PE
and/or FGR in preterm and term pregnancies (S2 and S3 Tables in S1 File). Additionally, male
and female fetuses presented the same profile of heme scavengers in the different phenotypes
of PE and/or FGR compared to controls (S4 and S5 Tables in S1 File).
No correlation existed between maternal and fetal hemopexin (r = 0.12, p = 0.12) or mater-
nal and fetal A1M (r = -0.01, p = 0.86), when looking at the whole population or within the
study groups.
None of maternal or fetal heme scavengers were correlated with time to delivery, maternal
morbidity, including severity and days of admission at the intensive care unit, or perinatal
morbidity such as low APGAR score at 5 minutes and neonatal intensive care admission.
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Discussion
Principal findings
This study demonstrates for the first time the differential involvement of heme scavengers
hemopexin and A1M in the different phenotypes of PE and/or FGR by investigating their con-
centrations in paired maternal and fetal blood samples. Our results show that the heme scaven-
ger systems have an altered profile in maternal blood in PE -with and without FGR- and in
fetal blood in FGR -with and without PE- in comparison to uncomplicated pregnancies.
In the present study, we reveal that PE mothers have lower hemopexin along with higher
A1M concentrations compared to controls. Conversely, fetuses who suffered FGR presented
lower levels of hemopexin and A1M than fetuses from uncomplicated pregnancies. These
results suggest that heme scavenger system is overwhelmed in PE mothers and FGR fetuses,
possibly due to hemoglobin-induced oxidative stress [11, 14]. Interestingly, A1M behaved dif-
ferently in maternal and fetal circulations, being elevated in the mother while it was reduced in
Table 1. Maternal, fetoplacental and perinatal characteristics of the study population.
Controls FGR PE PE&FGR
N = 49 N = 47 N = 45 N = 51
Maternal characteristics
Age (years) 35.1 (31.1–37.3) 34.7 (29.3–38.8) 33.6 (30.5–36.9) 34.9 (31.6–37.6)
Caucasian ethnicity 28 (57.1) 36 (76.6)� 20 (44.4) 25 (49)
Pre-gestational BMI (Kg/m2) 22.9 (20.7–25.2) 21.5 (19.8–23.3)� 25.7 (22.4–29.3)� 24.1 (21–26.4)
Chronic hypertension 0 (0) 0 (0) 6 (13.3)� 6 (11.8)�
Pre-gestational diabetes 0 (0) 3 (6.4) 6 (13.3)� 1 (2)
Nulliparity 33 (67.4) 27 (57.5) 29 (64.4) 36 (70.6)
Assisted reproductive technologies 5 (10.2) 6 (12.8) 4 (8.9) 5 (9.8)
Smoking during pregnancy 4 (8.2) 12 (25.5)� 3 (6.7) 5 (9.8)
Feto-placental Doppler
Uterine arteries mean PI (z score) -0.22 (-1.26–0.94) 0.87 (-0.21–2.76)� -0.32 (-1.56–1.2) 2.69 (1.96–3.45)�
Umbilical artery PI (z score) -0.18 (-0.46–0.13) 0.22 (-0.25–1.4)� -0.31 (-0.53–0.12) 0.6 (0.14–1.49)�
Middle cerebral artery PI (z score) 0.01 (-0.32–0.92) -0.36 (-1.05–0.13)� -0.16 (-0.8–0.33) -0.84 (-1.66 –-0.25)�
Cerebroplacental ratio (z score) 0.01 (-0.56–0.86) -0.95 (-2.32–0.06)� -0.2 (-0.96–0.39) -1.53 (-2.43 –-0.66)�
Perinatal outcomes
Gestational age at delivery (weeks) 39 (36.4–40.3) 37.6 (36.1–38.4)� 37.3 (36.9–38.3)� 35.1 (32.9–37.1)�
Deliveries <37 weeks gestation 18 (36.7) 13 (27.7) 13 (28.9) 34 (66.7)
Deliveries <34 weeks gestation 3 (0.06) 7 (14.9) 2 (0.04) 16 (31.4)
Cesarean section 11 (22.5) 23 (48.9)� 29 (64.4)� 29 (56.9)�
Male sex 26 (53.1) 25 (53.2) 17 (37.8) 31 (60.8)
Birthweight (g) 3220 (2606–3664) 2170 (1760–2438)� 2948 (2660–3270) 1794 (1474–2330)�
Birth weight centile 56 (39–75) 1 (0–2)� 51 (21–81) 1 (0–3)�
APGAR score 5 min <7 0 (0) 0 (0) 1 (2.2) 2 (3.9)
Umbilical artery pH 7.19 (7.15–7.24) 7.23 (7.17–7.29) 7.21 (7.17–7.24) 7.23 (7.11–7.26)
Admission to neonatal intensive care unit 9 (18.4) 15 (31.9) 12 (26.7) 31 (60.8)�
Perinatal mortality 0 (0) 1 (2.2) 0 (0) 2 (3.9)
Data are presented as median (interquartile range) or n (%) as appropriate. BMI, body mass index; FGR, fetal growth restriction; PE, preeclampsia. Perinatal mortality
was defined as stillbirth or neonatal mortality within 28 days of delivery. The cerebroplacental ratio was calculated as the fetal middle cerebral artery PI divided by the
umbilical artery PI.
� p<0.05 by Mann Whitney U or Pearson χ2 tests as appropriate, compared to controls.
https://doi.org/10.1371/journal.pone.0239030.t001
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Fig 2. Concentrations of heme scavengers in maternal and fetal blood in the study population. Box plots represent a) maternal
hemopexin concentrations, b) maternal A1M concentrations, c) fetal hemopexin concentrations, d) fetal A1M concentrations.
Boxes show median and interquartile range, whiskers represent 1.5 Χ interquartile range or the extremes of the distribution. FGR,
fetal growth restriction; PE, preeclampsia; A1M, α1-microglobulin. p values were calculated by multiple regression (multivariate
linear regression) compared to controls, adjusted for chronic hypertension, diabetes, assisted reproductive technologies, smoking,
fetal sex and gestational age at sampling.
https://doi.org/10.1371/journal.pone.0239030.g002
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the fetus in contrast with depletion of hemopexin in both. A possible explanation to the differ-
ence in the behavior of hemopexin and A1M may be their different clearance routes. While
hemopexin-heme complexes get cleared through a specific receptor [33], A1M clearance is
dependent on the kidney filtration [34]. The filtration capacity becomes reduced in PE moth-
ers while in the developing fetus the placenta takes over the role of the kidney and permitting
A1M clearance [35, 36]. No correlation existed between maternal and fetal heme scavengers,
indicating that the concentrations of these biomarkers in maternal and fetal circulations are
independent of each other and reflect the status of the mother and the fetus, separately. Thus,
the heme scavenger systems seem to be affected in the mother or the fetus in isolated PE or
FGR, respectively, and in both the mother and the fetus when the two disorders coexist. Free
HbF, LDH activity and erythropoietin results were concordant reflecting a status of chronic
hypoxia in FGR fetuses particularly those from PE pregnancies.
Results of the study in the context of other observations
In recent publications, PE has been associated with increased levels of cell-free hemoglobin
and A1M together with lower haptoglobin and hemopexin [14, 21]. Our data are consistent
with these reports, and provide further evidence that both PE with and without FGR have the
same profile in maternal blood. In addition to this, we now show that there are no differences
in hemopexin and A1M levels between normotensive FGR mothers and controls. In line with
our results, studies have shown that the heme scavengers profile was similar in early and late-
onset PE, and have thus suggested them as biomarkers for the disorder [8, 21]. Their role in
predicting PE has also been investigated, showing that higher A1M and lower hemopexin lev-
els were present already from the first trimester in pregnancies that later developed PE [19,
20]. Moreover, a recent study showed that high-risk pregnancies without PE also had an
altered profile of heme scavengers compared to low-risk gestations [31]. Free HbF and heme
scavenger concentrations in cord blood were first explored by Brook et al showing an elevated
level of free HbF in FGR fetuses, which may contribute to increased fetoplacental vascular
resistance and impaired endothelial protection [9]. In the current study, we further demon-
strate that FGR fetuses have a similar profile of heme scavengers regardless of whether the
mother is normotensive or preeclamptic. Additionally, we show that fetuses from PE pregnan-
cies without FGR did not present any difference compared to controls. These findings were
independent of fetal sex in line with previous reports on comparable free HbF levels among
male and female fetuses [37, 38].
Pathophysiological mechanisms
Several studies have suggested that PE and FGR may originate in the first trimester developing
placental insufficiency associated with local hypoxia [5, 6]. Hypoxia, in turn, may lead to
increased erythropoiesis through the increased synthesis of erythropoietin, and induce a
switch from adult hemoglobin to HbF in cord blood cells [39, 40]. Free hemoglobin might par-
ticipate in oxidative damage to placental tissues and contribute to FGR and fetal compromise
[9]. In normotensive FGR, the damage may remain local, affecting primarily the developing
fetus, whereas in cases of disrupted blood–placenta barrier, free hemoglobin could leak to the
maternal circulation exerting systemic oxidative stress on the endothelium. Thus, free hemo-
globin in the maternal circulation could be fetal hemoglobin originating from the placenta, or
adult free hemoglobin originating from hemolysis of maternal red blood cells [14, 41]. In both
cases, free hemoglobin contributes to the oxidative stress and vasoconstriction seen in PE. In
the other phenotype of PE, PE without FGR, the heme scavenger system’s alterations could be
explained by maternal systemic maladaptation to the pregnancy manifesting by the maternal
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disease with subsequent late placental involvement [5, 42, 43]. In this case, the blood-placenta
barrier remains intact and the fetus stays unaffected with a clinical presentation as late-onset
PE principally.
Strengths and limitations
This was a prospective study with meticulous characterization of the included pregnancies in
addition to the collection of paired maternal and fetal blood samples at the time of delivery.
However, it was unfeasible to match cases with controls for gestational age at time of sampling
due to the greater proportion of elective deliveries in PE and/or FGR. We believe that the per-
ceived differences in heme scavengers could not be explicated by the difference in gestational
age at delivery, since the concentrations of hemopexin and A1M have been described to be
altered from the first trimester in pregnancies that developed PE [19, 20]. Moreover, we
applied careful statistical analysis adjusting our findings for potential confounders comprising
the gestational age. The current study was substantially composed of late-onset pregnancies,
which constitute the most prevalent form of placenta-mediated disorders, with quite a few
early-onset cases. Although we focused on hemopexin and A1M in this study, we believe that
assessing the albumin, other heme scavengers such as the haptoglobin and markers of oxida-
tive stress like oxidized lipids would be of interest. Moreover, investigating the changes in
heme scavengers through the pregnancy would complement our knowledge in terms of their
role in the early stages of gestation.
Conclusions and perspectives
Our results support the hypothesis that hemoglobin-induced oxidative stress contribute to the
pathogenesis in both PE and FGR. In addition, we highlight the differential involvement of
heme scavenger systems, which are responsible for protecting against this oxidative stress, in
accordance with the clinical presentation of PE and/or FGR. The scavengers hemopexin and
A1M presented significantly altered concentrations in maternal blood in the maternal disease
-PE- and in cord blood in the fetal disease -FGR-. Further research is warranted to identify the
precise effects of hemoglobin-induced oxidative stress on the mother and the fetus, to clarify
the placental behavior in the different phenotypes of PE and/or FGR and to determine poten-
tial interventional measures for the treatment or prevention of these disorders and their related
complications whereby scavenger protein-based therapeutics are potential candidates [12, 44].
Of interest, recombinant A1M has shown a protective role against organ damage and FGR in
preeclampsia mouse model, ewe and rabbits as well [45–47]. Human studies are necessitated
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